31 October 2023 - Today, the US FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory diseases. 

Wezlana, like Stelara, is approved to treat:

Adult patients with:

• Moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
• Active psoriatic arthritis
• Moderately to severely active Crohn’s disease
• Moderately to severely active ulcerative colitis

Paediatric patients 6 years of age and older with:

• Moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
• Active psoriatic arthritis

Read FDA press release